House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Pancreatitis

NICE · 2020 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (NG104, Pancreatitis) covers the diagnosis and management of acute, chronic and hereditary pancreatitis in adults and children. One recommendation carries a '2018, amended 2020' label. The guideline also includes notes on the September 2024 disruption to pancreatic enzyme replacement therapy (PERT) supplies. It addresses patient information and lifestyle advice. For acute pancreatitis, it covers identifying the cause, infection prevention, nutrition, management of infected necrosis and specialist referral. For chronic pancreatitis, it covers recognition, nutrition, duct obstruction, pseudocysts, type 3c diabetes and long-term surveillance. Several topics are deferred to other NICE guidelines.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Information, support and lifestyle

  • Give people with pancreatitis, and their family or carers as appropriate, written and verbal information where relevant, as soon as possible after diagnosis. This should cover hereditary and childhood pancreatitis, including genetic counselling, genetic testing and risk to relatives. It should also cover long-term effects, including effects on quality of life, and the harm smoking or alcohol causes to the pancreas. [1]
  • Where applicable, give written and verbal information on how pancreatitis is managed. Topics include multidisciplinary team care and multidisciplinary pain treatment. They also include nutrition advice, including how to take PERT, follow-up and whom to contact (including during acute illness), and psychological care if needed, where available. [1]
  • In severe acute pancreatitis, explain several points to patients and their family or carers as appropriate. Hospital stays of several months, including critical care, are relatively common. Full recovery may take at least 3 times the length of the hospital stay. Delaying intervention may be safer. People who have started to recover may relapse. [1]
  • Also explain to people with severe acute pancreatitis and their families that children rarely die from acute pancreatitis. However, about 15% to 20% of adults with severe disease die in hospital. [1]
  • Information passed to GPs should include, where applicable, PERT instructions, including dose escalation. It should also state that the person should be offered HbA1c testing at least every 6 months and bone mineral density assessment every 2 years. [1]
  • Advise people whose pancreatitis is caused by alcohol to stop drinking. Tell those with non-alcohol-related recurrent acute or chronic pancreatitis that alcohol might worsen it. Advise people with chronic pancreatitis to stop smoking. [1]

Acute pancreatitis: diagnosis and cause

  • As context, the guideline notes that raised blood lipase or amylase usually confirms the diagnosis, although these can rise in other conditions. If levels are not raised, abdominal CT may confirm pancreatic inflammation. [1]
  • Do not attribute acute pancreatitis to alcohol solely because the person drinks. [1]
  • Once gallstones and alcohol are excluded, look for other causes. These include metabolic causes (hypercalcaemia, hyperlipidaemia), prescription drugs, microlithiasis, hereditary causes, autoimmune pancreatitis, ampullary or pancreatic tumours, and pancreas divisum. [1]

Acute pancreatitis: management and referral

  • Prophylactic antimicrobials should not be offered in acute pancreatitis. [1]
  • Do not make patients nil-by-mouth or withhold food unless there is a clear reason, such as vomiting. [1]
  • In severe or moderately severe acute pancreatitis, offer enteral nutrition, started within 72 hours of presentation, and aim to meet nutritional requirements promptly. Offer parenteral nutrition only if enteral nutrition has failed or is contraindicated. [1]
  • Severity definitions follow the revised Atlanta classification. Moderately severe disease means organ failure resolving within 48 hours, or local or systemic complications without persistent organ failure. Severe disease means organ failure persisting beyond 48 hours. [1]
  • For infected or suspected infected necrosis, offer an endoscopic approach when anatomically possible, otherwise a percutaneous approach. When deciding on management, weigh prompt debridement against the advantages of delaying intervention. [1]
  • If necrotic, infective, haemorrhagic or systemic complications develop, seek advice from a specialist pancreatic centre in the referral network. Discuss transfer there for treatment of the complications. When managing acute pancreatitis in children, seek advice from a paediatric gastroenterology or hepatology unit and a specialist pancreatic centre, and discuss transfer. [1]

Chronic pancreatitis: recognition and nutrition

  • Think about chronic pancreatitis in people with chronic or recurrent upper abdominal pain, and refer accordingly. Do not assume alcohol is the cause. Other causes include genetic factors, autoimmune disease (especially IgG4 disease), metabolic causes and structural or anatomical factors. [1]
  • All people with chronic pancreatitis are at high risk of malabsorption and malnutrition. Use protocols agreed with the specialist centre to decide when specialist dietitian advice is needed, including on food, supplements and long-term PERT, and when to start these. Consider dietitian assessment for everyone diagnosed. [1]

Chronic pancreatitis: complications

  • In adults with painful chronic pancreatitis obstructing the main duct, consider surgery (open or minimally invasive) as first-line treatment. If surgery is unsuitable and a dominant stone causes the obstruction, consider extracorporeal shockwave lithotripsy. [1]
  • For symptomatic pseudocysts (for example pain, vomiting or weight loss), offer EUS-guided drainage. Endoscopic transpapillary drainage is an alternative for pancreatic head pseudocysts. [1]
  • For asymptomatic pseudocysts, consider the same endoscopic drainage if any of the following apply: duct disruption, pressure on large vessels or the diaphragm, rupture risk, or suspected infection. Consider laparoscopic or open surgical drainage if endoscopic therapy is unsuitable or has failed. [1]
  • Consider specialist pancreatic centre referral for pancreatic ascites and pleural effusion. The acute pancreatitis section cross-refers to these chronic pancreatitis recommendations for pseudocysts and for ascites and pleural effusion secondary to pancreatitis. [1]
  • Type 3c diabetes is secondary to pancreatic disease; when associated with pancreatitis, the primary defect is insufficient insulin secretion. Assess affected people every 6 months for potential benefit from insulin therapy. [1]

Chronic pancreatitis: follow-up and surveillance

  • Offer clinical and biochemical monitoring, agreed with the specialist centre, for exocrine insufficiency and malnutrition. Monitoring should be at least every 12 months, or every 6 months in under 16s, with vitamin and mineral treatment adjusted accordingly. Offer adults bone density assessment every 2 years. [1]
  • Chronic pancreatitis raises pancreatic cancer risk, with lifetime risk around 40% in hereditary pancreatitis. Consider annual cancer monitoring in hereditary pancreatitis. [1]
  • Lifetime diabetes risk in chronic pancreatitis may reach 80%. Risk rises with disease duration and calcific disease. Offer HbA1c monitoring at least every 6 months. [1]

Limitations and use

  • Research recommendations and rationale sections are not covered. The guideline makes no recommendation on a diagnostic test for chronic pancreatitis when CT, ultrasound or endoscopy is inconclusive; this is a research recommendation only.
  • Several topics are deferred to other NICE guidelines and are not summarised here. These are fluid resuscitation, alcohol-use disorders, neuropathic pain, nutrition support and detailed management of type 3c diabetes (non-insulin and insulin treatment, education and glucose monitoring).
  • PERT supply was disrupted in September 2024. The guideline directs prescribers to the Specialist Pharmacy Service resource to identify equivalent licensed products.
  • Some recommendations are restricted to adults: surgery and lithotripsy for duct obstruction, bone density assessment, and neuropathic pain. Monitoring frequency for exocrine function differs in under 16s.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Pancreatitis

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
5 September 2018
Publisher’s latest update
16 December 2020
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Information, support and lifestyle
  • Acute pancreatitis: diagnosis and cause
  • Acute pancreatitis: management and referral
  • Chronic pancreatitis: recognition and nutrition
  • Chronic pancreatitis: complications
  • Chronic pancreatitis: follow-up and surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House